1-4 of 4
Giuseppe Lamberti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V. Alessi, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Lingzhi Hong, Jianjun Zhang, John V. Heymach, Don L. Gibbons, Andrew J. Plodkowski, Vignesh Ravichandran, Mark T.A. Donoghue, Chad Vanderbilt, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely, Jamie E. Chaft, Matthew D. Hellmann, Natalie I. Vokes, Mark M. Awad, Adam J. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4408–4418.
https://doi.org/10.1158/1078-0432.CCR-23-1207
Published: 01 November 2023
View article titled, Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer

Biagio Ricciuti, Arielle Elkrief, Joao Alessi, Xinan Wang, Yvonne Li, Hersh Gupta, Daniel M. Muldoon, Arrien A. Bertram, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Adriana Barrichello, Victor R. Vaz, Malini Gandhi, Elinton Lee, Geoffrey I. Shapiro, Hyesun Park, Mizuki Nishino, James Lindsay, Kristen D. Felt, Bijaya Sharma, Andrew D. Cherniack, Scott Rodig, Daniel R. Gomez, Narek Shaverdian, Mehrdad Rakaee, Chaitanya Bandlamudi, Marc Ladanyi, Pasi A. Janne, Adam J. Schoenfeld, Lynette M. Sholl, Mark M. Awad, Michael L. Cheng
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2540–2550.
https://doi.org/10.1158/1078-0432.CCR-22-3413
Published: 05 July 2023
View article titled, Clinicopathologic, Genomic, and Immunophenotypic Landscape of <em>ATM</em> Mutations in Non–Small Cell Lung Cancer
Open the PDF for Clinicopathologic, Genomic, and Immunophenotypic Landscape of <em>ATM</em> Mutations in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer

Biagio Ricciuti, Gonzalo Recondo, Liam F. Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette M. Sholl, Geoffrey I. Shapiro, Mark M. Awad, Michael L. Cheng
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4135–4142.
https://doi.org/10.1158/1078-0432.CCR-19-3529
Published: 03 August 2020
View article titled, Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
Open the PDF for Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi, Ying-Chun Lo, Yvonne Y. Li, Giuseppe Lamberti, Tom Nguyen, Marina S.D. Milan, Deepti Venkatraman, Renato Umeton, Cloud P. Paweletz, Adem Albayrak, Andrew D. Cherniack, Kristin S. Price, Stephen R. Fairclough, Mizuki Nishino, Lynette M. Sholl, Geoffrey R. Oxnard, Pasi A. Jänne, Mark M. Awad
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2615–2625.
https://doi.org/10.1158/1078-0432.CCR-19-3608
Published: 01 June 2020
View article titled, Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Open the PDF for Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC in another window
Includes: Supplementary data